jameshebrew  lumikha ng bagong artikulo
3 taon

The gene-editing beyond CRISPR market is anticipated to grow at an annualized rate of 18% | #gene editing market # Gene-Editing Beyond CRISPR

The gene-editing beyond CRISPR market is anticipated to grow at an annualized rate of 18%

The gene-editing beyond CRISPR market is anticipated to grow at an annualized rate of 18%

With the approval of HUMULIN®, the first genetically modified drug, scientific community has made significant progress in developing gene edited therapies based on programmable nucleases, such as ZFNs, TALENs, EMNs and CRISPR.
Gusto